Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Aposense Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Aposense Ltd.
ClinicalTrials.gov Identifier:
NCT01260480
First received: December 14, 2010
Last updated: December 16, 2010
Last verified: December 2010

December 14, 2010
December 16, 2010
December 2010
February 2012   (final data collection date for primary outcome measure)
To characterize changes in [18F]-ML-10 uptake in the target lesion in response to chemoradiotherapy. [ Time Frame: Between baseline and day 11 ± 1, and between baseline and day 18 ± 1 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01260480 on ClinicalTrials.gov Archive Site
  • To assess the correlation between the changes in the uptake of [18F]-ML-10 in the target lesion and the changes in the anatomical dimensions of the target lesion. [ Designated as safety issue: No ]
    To assess the correlation between the changes in the uptake of [18F]-ML-10 in the target lesion following an accumulative radiation dose of 14.4-20.0 Gy, and the changes in the anatomical dimensions of the target lesion, as assessed by the follow-up anatomical imaging by CT, performed after completion of the concurrent chemoradiotherapy (CRT).
  • To identify at least one parameter, derived from the changes in [18F]-ML-10 uptake that can discriminate tumors responsive to treatment from tumors that are non-responsive. [ Designated as safety issue: No ]
    For this parameter, various cut-off values of change will be evaluated, with corresponding estimates of sensitivity and specificity.
  • To perform additional analyses for all other lesions and lymph nodes with at least one diameter ≥ 2 cm treated by concurrent CRT. [ Designated as safety issue: No ]
  • To assess the safety of [18F]-ML-10 administered to cancer patients receiving concurrent CRT. [ Designated as safety issue: Yes ]
  • To assess the correlation between the changes in the uptake of [18F]-ML-10 in the target lesion and the changes in the anatomical dimensions of the target lesion. [ Designated as safety issue: No ]
    To assess the correlation between the changes in the uptake of [18F]-ML-10 in the target lesion following an accumulative radiation dose of 14.4-20.0 Gy, and the changes in the anatomical dimensions of the target lesion, as assessed by the follow-up anatomical imaging by CT, performed after completion of the concurrent CRT.
  • To identify at least one parameter, derived from the changes in [18F]-ML-10 uptake that can discriminate tumors responsive to treatment from tumors that are non-responsive. [ Designated as safety issue: No ]
    For this parameter, various cut-off values of change will be evaluated, with corresponding estimates of sensitivity and specificity.
  • To perform additional analyses for all other lesions and lymph nodes with at least one diameter ≥ 2 cm treated by concurrent CRT. [ Designated as safety issue: No ]
  • To assess the safety of [18F]-ML-10 administered to cancer patients receiving concurrent CRT. [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy

The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to chemoradiation therapy.

The study will evaluate the potential of [18F]-ML-10 used in conjunction with PET imaging to distinguish early during the course of chemoradiation therapy between a tumor that responds to the therapy, and a tumor that does not respond to the therapy. Currently, this distinction is available to the physician several weeks or months after completion of therapy, using anatomical imaging (for example Computed Tomography [CT] or Magnetic Resonance Imaging [MRI]).

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Carcinoma, Non-Small-Cell Lung
  • Head and Neck Neoplasms
Other: [18F]-ML-10 in conjunction with PET imaging
Subjects will receive two to three intravenous (IV) doses of [18F]-ML-10. The dose for each [18F]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
Experimental: [18F]-ML-10
Intervention: Other: [18F]-ML-10 in conjunction with PET imaging
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
Not Provided
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Male or female patients with either:

Newly diagnosed non small cell lung cancer (NSCLC) (Group A) who meet the following criteria:

  • Previously untreated, histologically or cytologically confirmed stage IIB, IIIA or IIIB disease, without evidence of distant metastases
  • A measurable primary tumor with at least one diameter > 2 cm or primary tumor extending to one or more lymph nodes which cannot be distinctively delineated as confirmed by a diagnostic quality chest CT performed within 4 weeks prior to initiation of the concurrent CRT.
  • Planned to receive concurrent chemoradiotherapy as definitive treatment. The radiation dose should not exceed 70 Gy.
  • Undergone the following minimum workup to confirm disease staging within 4 weeks prior to initiation of the concurrent CRT:

    • GBCA-enhanced Brain MRI or contrast enhanced CT if there are signs or symptoms suggesting brain metastases within the past 2 months.
    • If necessary to confirm stage of disease, an upper abdomen CT scan will be performed.
    • whole-body FDG PET/CT; OR
  • Newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) (Group B) who meet the following criteria:

    • Previously untreated, histologically or cytologically confirmed (from the primary tumor and/or lymph nodes) stage III-IV disease without evidence of distant metastases.
    • A measurable (i) primary tumor with at least one diameter ≥2 cm and (ii) lymph node with at least one diameter ≥ 2 cm as confirmed by a diagnostic quality neck CT performed within 4 weeks prior to initiation of the concurrent CRT.
    • Planned to receive concurrent chemoradiotherapy as definitive treatment. The radiation dose should not exceed 70 Gy.
    • Have undergone the following minimum workup to confirm disease staging within 4 weeks prior to initiation of the concurrent CRT:
  • Whole-body FDG PET/CT.
  • Patients ≥ 18 years of age.
  • Able to comply with lying still during the PET/CT imaging session which may last for up to 3 hrs with intermediate breaks.
  • ECOG performance status of 0, 1 or 2.
  • Adequate renal function and adequate hepatic function, as assessed by standard laboratory criteria and defined as:
  • Serum creatinine ≤ 1.2 times the Upper Limit of Normal (ULN).
  • Total bilirubin ≤ 1.5 times the ULN.
  • Asparagine aminotransferase (AST) and/or alanineaminotransferase (ALT) ≤ 2.5 times the ULN (grade 1 according to the NCI-CTCAE v.3).
  • Women of child-bearing potential must have a negative blood pregnancy test at screening and use an adequate and medically acceptable contraceptive method.
  • Willing and able to comply with the protocol requirements.
  • Able to provide written informed consent.

Exclusion Criteria:

Exclusion criteria specific to patients with NSCLC (Group A):

  • Predominant small cell carcinoma histology.
  • Pure bronchioalveolar cell carcinoma histology.
  • Treatment planned with chemotherapy other than a platinum-based doublet regimen.
  • Malignant pleural or pericardial effusions.
  • Any contraindication to perform CT with IV contrast agent.

Exclusion criteria specific to patients with SCCHN (Group B):

  • Histology other than squamous cell carcinoma.
  • Treatment planned with chemotherapy other than a platinum-based regimen.
  • Treatment planned with cetuximab.
  • Treatment with induction chemotherapy.
  • Any contraindication to CT with IV contrast agent.
  • Evidence of distant metastases.
  • Patients who, based on the investigator's judgment, have other unstable medical conditions that may preclude safe and complete study participation.
  • Treatment with any investigational drug, device or biologic agent within 30 days prior to administration of [18F]-ML-10.
  • Pregnancy or lactation.
Both
18 Years and older
No
United States
 
NCT01260480
NST-CA007
No
Yael Cohen, Aposense
Aposense Ltd.
Not Provided
Principal Investigator: Heron Dwight, MD University of Pittsburgh
Principal Investigator: David Sher, MD, MPH BWH, Harvard
Study Director: Aaron Allen, MD Rabin Medical Center
Aposense Ltd.
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP